Dear members of the ESC Working Group on Atherosclerosis and Vascular Biology,
After being affected by the Covid-19 pandemic in our personal and professional lives for more than two years, we are delighted to have the opportunity to meet you in a few weeks at the Frontiers in CardioVascular Biomedicine Congress (FCVB) held in Budapest (Hungary) from the 28th of April to the 1st of May, 2022. Your Working Group has made a significant contribution to the exciting scientific agenda. World-leading experts will discuss about vascular metabolic syndrome, cell heterogeneity in atherosclerosis based on single cell analysis of distinct cell types (inflammatory, smooth muscle, and endothelial cells), and inflammation in atherosclerosis.
One of the sessions will be dedicated to the physiological and pathological cardiovascular ageing. The role of structural vascular cells and inflammation in these processes will be addressed both mechanistically and translationally. This discussion will serve as a basis for a new position paper, that will be of great interest for our members.
Claudia Monaco (University of Oxford, UK), one of our Nucleus members, comments for you on her excellent paper “C-type lectin receptor CLEC4A2 promotes tissue adaptation of macrophages and protects against atherosclerosis”, which was recently published in the renowned journal Nature Communications. This study shed light on the unexpected athero-protective role of CLEC4A2 positive vascular macrophages.
On behalf of the Nucleus Members of the Working Group on Atherosclerosis and Vascular Biology, we are very much looking forward to meeting you in person during the FCVB 2022!
Marie-Luce Bochaton-Piallat, Chair
Konstantinos Stellos, Communication Coordinator
Our mission: To reduce the burden of cardiovascular disease.